[go: up one dir, main page]

DE69433013D1 - Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten - Google Patents

Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten

Info

Publication number
DE69433013D1
DE69433013D1 DE69433013T DE69433013T DE69433013D1 DE 69433013 D1 DE69433013 D1 DE 69433013D1 DE 69433013 T DE69433013 T DE 69433013T DE 69433013 T DE69433013 T DE 69433013T DE 69433013 D1 DE69433013 D1 DE 69433013D1
Authority
DE
Germany
Prior art keywords
growth factor
cancer
present
antibodies specific
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433013T
Other languages
English (en)
Other versions
DE69433013T2 (de
Inventor
Carol A Nacy
John W Holaday
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of DE69433013D1 publication Critical patent/DE69433013D1/de
Application granted granted Critical
Publication of DE69433013T2 publication Critical patent/DE69433013T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69433013T 1993-05-27 1994-05-26 Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten Expired - Fee Related DE69433013T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6871793A 1993-05-27 1993-05-27
US68717 1993-05-27
PCT/US1994/005927 WO1994027635A1 (en) 1993-05-27 1994-05-26 Compositions and methods for treating cancer and hyperproliferative disorders

Publications (2)

Publication Number Publication Date
DE69433013D1 true DE69433013D1 (de) 2003-09-11
DE69433013T2 DE69433013T2 (de) 2004-06-03

Family

ID=22084279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433013T Expired - Fee Related DE69433013T2 (de) 1993-05-27 1994-05-26 Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten

Country Status (10)

Country Link
US (1) US5919459A (de)
EP (1) EP0702563B1 (de)
JP (2) JPH08510751A (de)
AT (1) ATE246513T1 (de)
AU (1) AU6989094A (de)
CA (1) CA2163652A1 (de)
DE (1) DE69433013T2 (de)
DK (1) DK0702563T3 (de)
ES (1) ES2204919T3 (de)
WO (1) WO1994027635A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
US6805865B1 (en) * 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
JP2002531515A (ja) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド 水に難溶性の薬剤のための自己乳化組成物
WO2000053219A2 (en) * 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
US20020012651A1 (en) * 2000-05-10 2002-01-31 Loeb Marvin P. Release of therapeutic agents in a vessel or tissue
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
AU2002320079A1 (en) * 2001-06-11 2002-12-23 Jeong-Im Sin Vaccines, immunotherapeutics and methods of using the same
JP4685350B2 (ja) * 2001-07-26 2011-05-18 オタゴ イノベイション リミティド 抗原性組成物
CA2490129A1 (en) * 2002-06-26 2004-01-08 Entremed, Inc. Compositions and methods comprising protein activated receptor antagonists
EP1587484A4 (de) * 2002-12-19 2008-11-12 Alza Corp Verfahren zur behandlung von angiogenemgewebswachstum
JP2006526025A (ja) * 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
DE10333509B4 (de) * 2003-07-18 2007-05-03 Technische Universität Dresden Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
JP2007529426A (ja) * 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CA2587448A1 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8399440B2 (en) * 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20080234243A1 (en) * 2007-01-31 2008-09-25 Lavallee Theresa M Method of treating amyloidosis mediated diseases
EP2134352A4 (de) * 2007-03-05 2011-05-25 Univ Leland Stanford Junior Wnt-zusammensetzungen und anwendungsverfahren dafür
JP2010523676A (ja) * 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
EP2413951A4 (de) 2009-04-03 2015-05-20 Univ Duke Formulierung zur herbeiführung einer breit reaktiven neutralisierung von hiv-antikörpern
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011140296A1 (en) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4879236A (en) * 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
WO1993025225A1 (en) * 1992-06-17 1993-12-23 University Of Massachusetts Medical Center Liposomal formulations for administering to cancer patients
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein

Also Published As

Publication number Publication date
US5919459A (en) 1999-07-06
EP0702563B1 (de) 2003-08-06
WO1994027635A1 (en) 1994-12-08
EP0702563A4 (de) 1997-10-01
AU6989094A (en) 1994-12-20
CA2163652A1 (en) 1994-12-08
JPH08510751A (ja) 1996-11-12
ES2204919T3 (es) 2004-05-01
ATE246513T1 (de) 2003-08-15
DE69433013T2 (de) 2004-06-03
DK0702563T3 (da) 2003-11-10
EP0702563A1 (de) 1996-03-27
JP2007262102A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ATE168272T1 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
BR9510575A (pt) Anticorpos monoclonais contra hiv-1 vacinas preparadas com eles
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
DE69433590D1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE3806565A1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE69213943T2 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE287958T1 (de) Verbesserte krebstherapie
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Vischer Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells
AT409086B (de) Neue verwendung von antikörpern als impfstoffe
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
JPH05508769A (ja) 細胞培養及び治療に有用なβ―アレチン

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee